Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy

Qun Zhang; Fangyuan Gao; Xue Yang; Ying Hu; Yao Liu; Yixin Hou; Yuxin Li; Bingbing Zhu; Shuaishuai Niu; Yunyi Huang; Xianbo Wang

doi:10.12659/MSM.924040

08 August 2020 : Clinical Research

Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy

Qun Zhang^1CDE, Fangyuan Gao^1CD, Xue Yang^1D, Ying Hu^1D, Yao Liu^1CD, Yixin Hou^1D, Yuxin Li^1D, Bingbing Zhu^2B, Shuaishuai Niu^1BF, Yunyi Huang^3B, Xianbo Wang^1ADG*

DOI: 10.12659/MSM.924040

Med Sci Monit 2020; 26:e924040

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Risk factor of probiotics dose for esophagogastric variceal rebleeding.

Probiotics dose group	n	Rebleeding n (%)	AHR* (95% CI)	P-value
<28 cDDD group	490	261 (53.3)	1.0	–
28–60 cDDD group	73	36 (49.3)	0.755 (0.529–1.078)	0.123
61–90 cDDD group	98	43 (43.9)	0.629 (0.452–0.874)	0.008
>90 cDDD group	43	16 (37.2)	0.442 (0.265–0.737)	0.002
for trends				0.001
AHR – adjusted hazard ratio; CI – confidence interval. ^* AHR represents multivariate-adjusted hazard ratio: etiology, comorbidity index, Child-Pugh class, MELD score, ALT, AST, TBIL, GGT, CREA, GLU, WBC, INR, secondary prophylaxis are adjusted using a Cox proportional hazard regression model.

Back to the Article

Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy

Your Privacy